2018


2017


2016


Brotto L, Brundage M, Hoskins P, Vergote I, Cervantes A, Casado H, Poveda A,


Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


• Jiang S, Chen B, Tu D. Inference on treatment-covariate interaction based on a nonparametric measure of treatment effects and censored survival data. Statist Med n/a, 2016.


- Tang PA, Hay AE, O’Callaghan CJ, Mittmann N, Chambers CR, Pater JL, Leighl NB. Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada. Current Oncology 23:


Bartlett JMS, Nielsen TO, Gao D, Gelmon KA, Quintayo MA, Starczynski J, Han L, Burnell MJ, Levine MN, Chen BE, Shepherd LE, Chapman JW. TLE3 is not a predictive


706-12, 2014.


- Robinson AG, Booth CM, Eisenhauer EA. Progression-free survival as an end-point in solid tumours - Perspectives from clinical trials and clinical practice. Eur J Can 50: 2303-8, 2014.

2013


Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Macdonald DA, Assouline SE, Brandwein J, Kamel-Reid S, Eisenhauer EA, Couban S, Caplan S, Foo A, Walsh W, Leber B. A Phase I/II Study of Sorafenib (BAY 43-9006) In Combination with Low Dose Cytarabine (LDAC) In Elderly Patients with AML or High-


2012


- Booth CM, Eisenhauer EA. Progression-Free Survival: Meaningful or Simply


- Jiang S, Tu D. Inference on the probability as a measurement of treatment effect under a density ratio model and random censoring. Computational Statistics and Data Analysis 56: 1069-78, 2012.


paclitaxel/carboplatin with or without epirubicin (TEC versus TC) - a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. Ann Oncol 23: 2613-9, 2012.


2011


• Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P,


• O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrusis IL, Pritchard KI. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat 128: 401-9, 2011.


- Sargent D, Shi Q, Youthers G, Van CE, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A,
Buyse M, de GA. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47: 990-6, 2011.


2010


- Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase II study of docetaxel and prednisone with or


Mackay HJ, Gallinger S, Tsao MS, McLachlin CM, Tu D, Keiser K, Eisenhauer EA, Oza AM. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur J Can 46: 1365-73, 2010.


Tan X, Takahara G, Tu D. Optimal two-stage design for the phase II cancer clinical trials with responses and early progression as co-primary endpoints. Statistics in


2009


- Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC,


- Jang RW, Le Maître A, Ding K, Winton T, Bezjak A, Seymour L, Shepherd FA, Leighl NB. Quality-adjusted time without symptoms or toxicity analysis of adjuvant


2008


2007

- Brundage M, Osoba D, Bezjak A, Tu D, Palmer M, Pater J. Lessons Learned in the


- Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields ALA, Mayer RJ. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB


2006


Chapman J-AW, Lickley HLA, Trudeau ME, Hanna WM, Kahn HJ, Murray D, Sawka CA,


Tong FK, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib)
in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom 70: 107-14, 2006.


2005


2005.


2004


- Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R,

- Ma BBY, Oza A, Eisenhauer E, Stanimir G, Carey M, Chapman W, Latta E, Sidhu K,


2003


• Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D,


• Quirt I, Bodurtha A, Lohmann R, Rusthoven J, Belanger K, Young V, Wainman N,


2000


1999


1999

- Osoba D. What has been learned from measuring health-related quality of life in clinical oncology. Eur J Can 35: 1565-70, 1999.

1998


1997


• Osoba D, Aaronson N, Zee B, teVelde A, Sprangers M. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Quality of Life Research 6: 103-8, 1997.
• Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell V, Wierzbicki...


1996


- Dent S, Eisenhauer E. Phase I trial design: are new methodologies being put into practice? Ann Oncol 7: 561-6, 1996.


- Tu D, Gross AJ. A Bartlett type correction for the subject-years method in comparing


1995

- Latreille J, Stewart D, Laberge F, Hoskins P, Rusthoven J, McMurtrie E, Warr D, Yelle L,


1994

- Eisenhauer E, Lippman S, Kavanagh J, Parades-Espinoza M, Arnold A, Hong W,


- Niezgoda H, Pater J. A validation study of the domains of the core EORTC quality of life


1992


1991


Page 87 of 93


Bramwell V, Quirt I, Warr D, Verma S, Young V, Knowling M, Eisenhauer E. Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. A Canadian Sarcoma-NCI Canada Clinical Trials Group


1988


1987

- McCulloch P, Eisenhauer E, Shibata H, Young V. Phase II study of intravenous


1986


Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

70(9): 1133-6, 1986.

1985


1984


1980


1979